BDBM71065 US9546164, 210::US9694002, 210

SMILES: CCS(=O)(=O)NC(=O)c1cc(C2CC2)c(OCC2CCN(CC2)C(C)(C)c2cc(Cl)cc(Cl)c2)cc1F

InChI Key: InChIKey=REXMKIZHPWCXDF-UHFFFAOYSA-N

Data: 3 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 71065   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Sodium Channel Complex (Homo sapiens (Human))	BDBM71065 (US9546164, 210 | US9694002, 210) Show SMILES CCS(=O)(=O)NC(=O)c1cc(C2CC2)c(OCC2CCN(CC2)C(C)(C)c2cc(Cl)cc(Cl)c2)cc1F Show InChI InChI=1S/C27H33Cl2FN2O4S/c1-4-37(34,35)31-26(33)23-14-22(18-5-6-18)25(15-24(23)30)36-16-17-7-9-32(10-8-17)27(2,3)19-11-20(28)13-21(29)12-19/h11-15,17-18H,4-10,16H2,1-3H3,(H,31,33)	PDB UniProtKB/SwissProt antibodypedia antibodypedia antibodypedia antibodypedia antibodypedia antibodypedia antibodypedia antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.90	n/a	n/a	n/a	n/a	7.4	25
GENENTECH, INC.; XENON PHARMACEUTICALS INC. US Patent					Assay Description Binding of this radioligand was preformed in 5 mL borosilicate glass test tubes at room temperature. Binding was initiated by adding membranes to inc...				US Patent US9694002 (2017) BindingDB Entry DOI: 10.7270/Q24B2ZFG
					More data for this Ligand-Target Pair
Sodium channel protein type 5 subunit alpha (Homo sapiens (Human))	BDBM71065 (US9546164, 210 | US9694002, 210) Show SMILES CCS(=O)(=O)NC(=O)c1cc(C2CC2)c(OCC2CCN(CC2)C(C)(C)c2cc(Cl)cc(Cl)c2)cc1F Show InChI InChI=1S/C27H33Cl2FN2O4S/c1-4-37(34,35)31-26(33)23-14-22(18-5-6-18)25(15-24(23)30)36-16-17-7-9-32(10-8-17)27(2,3)19-11-20(28)13-21(29)12-19/h11-15,17-18H,4-10,16H2,1-3H3,(H,31,33)	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.90	n/a	n/a	n/a	n/a	7.4	25
GENENTECH, INC.; XENON PHARMACEUTICALS INC. US Patent					Assay Description Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) having a methyl group was tritiated. Three tritiums wer...				US Patent US9546164 (2017) BindingDB Entry DOI: 10.7270/Q2JD4ZS4
					More data for this Ligand-Target Pair
Sodium channel protein type 5 subunit alpha (Homo sapiens (Human))	BDBM71065 (US9546164, 210 | US9694002, 210) Show SMILES CCS(=O)(=O)NC(=O)c1cc(C2CC2)c(OCC2CCN(CC2)C(C)(C)c2cc(Cl)cc(Cl)c2)cc1F Show InChI InChI=1S/C27H33Cl2FN2O4S/c1-4-37(34,35)31-26(33)23-14-22(18-5-6-18)25(15-24(23)30)36-16-17-7-9-32(10-8-17)27(2,3)19-11-20(28)13-21(29)12-19/h11-15,17-18H,4-10,16H2,1-3H3,(H,31,33)	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.70	n/a	n/a	n/a	n/a	7.4	25
GENENTECH, INC.; XENON PHARMACEUTICALS INC. US Patent					Assay Description Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) having a methyl group was tritiated. Three tritiums wer...				US Patent US9546164 (2017) BindingDB Entry DOI: 10.7270/Q2JD4ZS4
					More data for this Ligand-Target Pair